Olmesartan Medoxomil Doc Generici

Olmesartan medoxomil, the active ingredient in Olmesartan Medoxomil Doc Generici, is an Angiotensin II receptor blocker (ARB) presented as a tablet for oral use. It is used to manage high blood pressure in adult patients. GNH USA supplies Olmesartan Medoxomil Doc Generici as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olmesartan Medoxomil Doc Generici as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan medoxomil is an ARB that lowers blood pressure by blocking the renin‑angiotensin system.

- Hypertension: helps lower systolic and diastolic blood pressure in adults. - Heart failure: used as part of combination therapy to improve cardiac function. - Diabetic nephropathy: slows progression of kidney damage associated with type 2 diabetes.

Olmesartan medoxomil may cause a range of adverse reactions.

Common Side Effects: - Dizziness - Headache - Fatigue - Nasal congestion - Diarrhea

Serious or Rare Side Effects: - Angio‑edema - Severe hypotension - Hyperkalemia - Acute kidney injury - Liver enzyme elevation

When prescribing Olmesartan medoxomil, clinicians should consider several safety aspects.

- Renal function: assess baseline kidney function and monitor periodically. - Electrolytes: check serum potassium, especially if combined with potassium‑sparing diuretics. - Pregnancy: contraindicated in the second and third trimesters due to fetal toxicity. - Elderly patients: start with lower doses and monitor for orthostatic hypotension. - Drug interactions: review concomitant medications that affect the renin‑angiotensin system. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Olmesartan medoxomil can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Aliskiren: combined use in diabetic patients may increase risk of renal impairment. - Potassium‑sparing diuretics: may cause dangerous hyper‑kalemia.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect and affect renal function. - Lithium: can increase serum lithium levels. - ACE inhibitors: concurrent use may increase risk of hypotension and renal dysfunction.